Hala JARRAR, Damla CETİN ALTİNDAL, Menemse GUMUSDERELİOGLU

The inhibitory effect of melatonin on osteoclastogenesis of RAW 264.7 cells in low concentrations of RANKL and MCSF

RAW 264.7 cells are one of the most recommended cell lines for investigating the activity and differentiation of osteoclasts. These cells differentiate into osteoclasts in the presence of two critical components: receptor activator of nuclear factor kappa B ligand (RANKL) and macrophage colony stimulating factor (MCSF). Melatonin (MEL) hormone has recently become one of the small molecules used in the field of bone regeneration and bone disease treatment, as it has the ability to inhibit the differentiation of osteoclasts directly by suppression of the NF-KB signaling pathway. The main aim of the current study is to determine sufficient RANKL/MCSF concentrations for differentiation of the cells to osteoclasts and to describe the repressive effect of MEL on the osteoclastogenesis of these cells. In this regard, it was found that 10 ng/mL of RANKL- and MCSF-containing medium is suitable for inducing osteoclastogenesis of the cells. In addition, melatonin at doses in the range of 100-1000 mu M does not have a cytotoxic effect. Subsequently, results of tartrate resistant acid phosphatase (TRAP) activity, TRAP staining, and relative expressions of cathepsin K, nuclear factor of activated T cells one (NFATC1), and TRAP genes showed a suppressive effect of MEL-especially 800 mu M-on RANKL-induced osteoclastogenesis of these cells.

Keywords:

RAW 264.7, melatonin RANKL, MCSF, osteoclast differentiation,

PDF

___

Ai-Aql ZS, 2008, J DENT RES, V87, P107, DOI 10.1177/154405910808700215
Altindal DC, 2019, J DRUG DELIV SCI TEC, V52, P586, DOI 10.1016/j.jddst.2019.05.027
Detsch R, 2016, NANOMEDICINE-UK, V11, P1093, DOI 10.2217/nnm.16.20
Fan X, 1997, J BONE MINER RES, V12, P1387, DOI 10.1359/jbmr.1997.12.9.1387
Germaini MM, 2017, BIOMED MATER, V12, DOI 10.1088/1748-605X/aa69c3
Ghayor C, 2011, J BIOL CHEM, V286, P24458, DOI 10.1074/jbc.M111.223297
Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
Hodge JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021462
Ichikawa H, 2006, MOL CANCER RES, V4, P275, DOI 10.1158/1541-7786.MCR-05-0227
Itoh K, 2001, ENDOCRINOLOGY, V142, P3656, DOI 10.1210/en.142.8.3656
Kaplan A, 2015, TURK J BIOL, V39, P879, DOI 10.3906/biy-1504-86
Kim HJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061142
Kim SE, 2012, J MATER SCI-MATER M, V23, P2739, DOI 10.1007/s10856-012-4729-9
Kohli Sarvraj Singh, 2011, Indian J Endocrinol Metab, V15, P175, DOI 10.4103/2230-8210.83401
Kong LB, 2019, J CELL MOL MED, V23, P3077, DOI 10.1111/jcmm.14277
Koyama H, 2002, J BONE MINER RES, V17, P1219, DOI 10.1359/jbmr.2002.17.7.1219
Liu J, 2013, INT J MOL SCI, V14, P10063, DOI 10.3390/ijms140510063
Park KH, 2011, J PINEAL RES, V51, P187, DOI 10.1111/j.1600-079X.2011.00875.x
Phiphatwatcharaded C, 2014, DRUG DEVELOP RES, V75, P235, DOI 10.1002/ddr.21177
Ping ZC, 2017, ACTA BIOMATER, V62, P362, DOI 10.1016/j.actbio.2017.08.046
Satue M, 2015, J CELL BIOCHEM, V116, P551, DOI 10.1002/jcb.25005
Tran KTM, 2017, J SCI-ADV MATER DEV, V2, P1, DOI 10.1016/j.jsamd.2016.12.001
Wang YJ, 2015, BIOTECHNOL ADV, V33, P1626, DOI 10.1016/j.biotechadv.2015.08.005
Xu JW, 2009, J ORTHOP RES, V27, P1306, DOI 10.1002/jor.20890
Zhou L, 2017, OSTEOPOROSIS INT, V28, P3325, DOI 10.1007/s00198-017-4127-8